News headlines about Intellia Therapeutics (NASDAQ:NTLA) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.4525618958814 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Intellia Therapeutics Inc. (NTLA) In State to Counters Short-Term Obligation – Stock News Stop (stockmarketstop.com)
- Intellia Therapeutics Inc. (NASDAQ: NTLA) – Trending Hot Stock’s Analysis – Alpha Beta Stock (alphabetastock.com)
- Intellia Therapeutics (NTLA) Receives “Hold” Rating from Oppenheimer (americanbankingnews.com)
- Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of … – GlobeNewswire (press release) (globenewswire.com)
- Intellia Therapeutics Inc (NASDAQ:NTLA) Further to Fall – Live Trading News (livetradingnews.com)
Intellia Therapeutics (NTLA) opened at $18.30 on Wednesday. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $33.34.
A number of equities analysts have weighed in on NTLA shares. Oppenheimer reiterated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. Credit Suisse Group lifted their price target on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Jefferies Group reiterated a “buy” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. Finally, Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $30.17.
In related news, CEO Nessan Bermingham sold 336,783 shares of Intellia Therapeutics stock in a transaction on Friday, December 8th. The shares were sold at an average price of $20.78, for a total transaction of $6,998,350.74. Following the transaction, the chief executive officer now owns 696,000 shares in the company, valued at approximately $14,462,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/13/intellia-therapeutics-ntla-receives-daily-media-impact-rating-of-0-12.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics and related companies.